-transparent.png){kind=logo}
The oxidative polymorphism of debrisoquine has been determined in 125 patients with bladder cancer and in 556 healthy control subjects; 96.6% of patients and 93.9% of controls with a metabolic ratio of debrisoquine less than 12.6 were classified as extensive metabolizers of debrisoquine (P = NS). The distribution of frequencies of metabolic ratio values tended to have lower values in the patients (P less than 0.05), reflecting a higher oxidative rate of debrisoquine in urothelioma patients that cannot be explained solely in terms of enzymatic induction by drugs, tobacco or alcohol. Patients with a high occupational risk for urothelioma had lower metabolic ratio values (P = 0.03). Our results suggest that oxidative polymorphism of debrisoquine might be related to the pathogenesis of bladder cancer.
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
January 1986,
Progress in clinical and biological research,
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
September 1984,
Carcinogenesis,
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
January 1988,
Cancer chemotherapy and pharmacology,
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
February 1982,
Clinical pharmacology and therapeutics,
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
January 1992,
European journal of clinical pharmacology,
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
February 1990,
British journal of clinical pharmacology,
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
October 1977,
Lancet (London, England),
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
September 1977,
Lancet (London, England),
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
August 1995,
British journal of clinical pharmacology,
J Benítez, and
J M Ladero, and
M J Fernández-Gundín, and
A Llerena, and
J Cobaleda, and
C Martínez, and
J J Muñoz, and
E Vargas, and
J Prados, and
F González-Rozas
January 1980,
British journal of clinical pharmacology,
